MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Orthostatic hypotension(OH)"

  • 2019 International Congress

    Changes in Supine Blood Pressure with Long Term Use of Droxidopa

    S. Gorny, L. Hewitt, A. Lindsten, M. Karnik-Henry, S. Kymes, A. Favit (Deerfield, IL, USA)

    Objective: To determine the long-term effects of droxidopa use on supine blood pressure (BP) in patients with neurogenic orthostatic hypotension (nOH). Background: nOH is a…
  • 2019 International Congress

    A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

    H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

    Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…
  • 2019 International Congress

    A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

    H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

    Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…
  • 2019 International Congress

    Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)

    A. Lo, J. Kanodia, R. Vickery, D. Bourdet (South San Francisco, CA, USA)

    Objective: To characterize the Phase 2 pharmacokinetics (PK) and pharmacodynamics (PD) of ampreloxetine in patients with nOH and provide dosing recommendations for special populations in…
  • 2019 International Congress

    Differences in correlation with cardiac sympathetic denervation between depression and anhedonia in drug naïve Parkinson disease patients

    H. Murakami, T. Shiraishi, T. Umehara, S. Omoto, H. Motegi, R. Nakada, T. Sato, A. Onda, H. Matsuno, T. Komatsu, K. Bono, K. Sakai, H. Mitsumura, Y. Iguchi (Tokyo, Japan)

    Objective: To compare the correlation with some assessments of DAT scan and myocardial MIBG scintigraphy between depression and anhedonia in drug naive Parkinson's Disease (PD)…
  • 2018 International Congress

    Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study

    K. Thiankhaw, S. Tanprawate, A. Soontornpun, A. Nudsasarn, S. Chankrachang (Chiang Mai, Thailand)

    Objective: To determine the effect and risk factors of a single dose levodopa induced OH in PD Background: Levodopa (LD) is widely recognised as the…
  • 2018 International Congress

    Droxidopa and Midodrine Treatment Persistence in Patients with Orthostatic Hypotension

    S. Kymes, K. Jackson, M. Widolff, C. Sullivan, L. Hewitt, S. Raj (Deerfield, IL, USA)

    Objective: To determine the treatment persistence of droxidopa and midodrine in patients with orthostatic hypotension (OH) or neurogenic orthostatic hypotension (nOH) when medication cost was…
  • 2018 International Congress

    Effects of orthostatic hypotension and supine hypertension on cognition in Parkinson’s disease

    H. Jeong (Changwon, Republic of Korea)

    Objective: The purpose of this study was to investigate the correlation of hemodynamic parameters and cognition in patients with PD. Background: Cognitive impairment is common…
  • 2018 International Congress

    Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure

    S. Hegde, M. Pulido-Rios, A. McNamara, J. Smith, W. Smith, J. Kanodia, D. Bourdet (South San Francisco, CA, USA)

    Objective: TD-9855 is a novel NET inhibitor (1) being studied for the treatment of symptomatic nOH. The objective of the present study was to characterize…
  • 2017 International Congress

    Where Are The Main Lesions That Cause Orthostatic Hypotension In Parkinson’s Disease ?

    R. Sengoku, M. Shibukawa, M. Yamazaki, K. Eguchi, M. Higashihara, D. Kaneda, Y. Nishina, K. Kanemaru, S. Murayama (Tokyo, Japan)

    Objective: To clarify the responsible lesion of orthostatic hypotension (OH) in Parkinson’s disease (PD) by measuring the catecholamine level and using a cardiac MIBG scintigraphy.…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley